At the end of 2022, the RADAR-AD participating clinical centre in Geneva (Switzerland) included the 220th and final participant in the RADAR-AD study. This represents a significant milestone for the RADAR-AD clinical trial which has met its recruitment targets in all three tiers – thereby meeting an important project goal. Read more, here: https://www.radar-ad.org/newsroom/radar-ad-includes-last-participant-its-clinical-study
